provide the a I Carrie, our thank to of will as first making review we're detail call with begin our over for to then well you, call results. joining everyone, our us results across Thanks, to turn today and focus drive progress financial areas on will this David afternoon. our I quarter growth, core the more as
publications installed quarter Seer, the Even the a more of effort initiation making and customers, we're studies the start $X.X by and customer in more in through the had tremendous peer population-scale we the of revenue first million year their interest our growth in studies, solid and continued the entire team base. data to seeing the to and being at growing importantly, our first review increasingly process. ended with Thanks a larger more shared way with
the now Mass said be that market, We ASMS, is consistently we're the conference or at public critical to what presentation additional more seeing. of the with expected annual Spectrometry, Society Seer's XXX customers in exactly than have Technology and and the We data have publication this increased to early will on third-party developing American June. date data of
our year-over-year for the $XX XXXX With revenue reiterating growth continue significant in of guidance to this XX% XXXX, range representing to of solid million $XX to start, expect XX%. we're and million
to continue sheet. we a While drive on advancement multiyear we're cash, expenses we're top over order protect and the in $XXX of balance can approach a are and resilient organization plan strategic medicine. taking a building to our operating a that disciplined With our million to growth, on well make positioned line impact very execute with robust science meaningful
for the We're leveraging investors proteomics human our creating innovation, to and drive of and contributing field resources health overall. and the our value positive committed customers trajectory to
year, this across on call we're areas. As our earnings mentioned, on focused X the core last executing
Product fourth, finally, with markets; and expanding applications our the power team. technology; discoveries Suite; catalyzing Proteograph new our breakthrough enabling First, of the and second, industry-leading third, demonstrating
enable. needs allowing growing the We're the by hands. many Product our extensible Suite providing workflow proteome us can unmet objective. to unbiased with reproducible address is for in what first access flexibility Proteograph the to customers' with our Starting The is highly scale, Proteograph and enthusiasm and encouraged
BioRxiv. to as of has is remarks, in my a Suite Physiology biological more preprint protein variant Product analysis. available customer the publicly. perform of to milestone value first Cornell which now that exemplified. view important Karsten data trait data shared mentioned opening connecting study the loci been unbiased This has robustly peptide and quantitative Medicine, peer in manuscript in as an a multiomic review I deep the as is pQTL Dr. Weill or is Biophysics data the under and using researchers at being I Suhre, level a leading genomic this Professor As Proteograph study a proteomic
genetic Dr. In allowing of diabetic plasma protein the among peptides subjects and subjects. XXX associated a cohort study proteins these study, identified XX,XXX variation and identify in to and them controls, approximately X,XXX Suhre over across concentration with variants
Dr. the Suite the to reagent. of of abundance which the impacted is epitope affinity-based affinity be peptide Product to a understand shortcoming deeply of work Proteograph deliver uniquely the Importantly, more protein protein-altering their this publication approaches of by able variants at highlights which importance may binding target measured highlights the resolution scale. Suhre's changed the in that level proteome,
diabetes protein certain The Another via example, of level. biologically human in solution the spec-based for problem targeted with range obesity detecting across this for intended provides highly shown active application this failure post-translationally the interesting to spectrometry high-value and and the the Proteograph a targeted proteins, has concentrations combination for Proteograph proteomics wide reproducible a in including mass target approach method for is research workflow emerging on peptide exclusively diabetes combined serum rely publications and specific detect of of quantifying at workflows mass the forms. barriers antibodies modified limitations, plasma research. with Most a today quantifying obesity the have desired assays to robust, and
proteomics is who's Van and the a Institute Van Advanced leading and work. Biosystem Precision Cardiology an clinical Proteograph at the Clinical to quantify of that inaccessible the to Eyk, Biomarker Suite Director Research Professor is of of the labs Cedars-Sinai international clinically relevant biomarkers or leveraged current founder Dr. Jenny Eyk are Dr. Product has this Organization, team identify leader HUPO. Proteome Her and Human immunoassays. President of in and
plasma several lower using Proteograph also of by monitoring contain of not other that the proteins may while performed they methods hundred accessible accurate proteins ensures targeted are the which proteomics easily biomarker interest, The quantitation workflow, standard needs. additional allowing abundance of
and studies treatment for allows large-scale be into can stratify diabetic a patients for of method and an groups. diagnostic that this quick the service potential completion optimal obese rapid in as turnaround assay to offered Importantly,
team presented at that by of and diseases data funded assay mass year. publication Kidney National last up the diabetes in and meeting are scaling of spectrometry Digestive and the the and year is evaluation in Diabetes this process late Her the obesity Institute toward later this Proteograph research study the currently targeted
illustration can and the with possible to have research Van applications in its clinical workflow needs is that not Proteograph potential customers Dr. been the great speaks Eyk's that of deliver hands address the of new to a unmet existing methods. directly
multiomic announced they what lung PrognomIQ be believe or early improve and study specificity study detection early results biomarker and deep our to non-cancer with multiomic sensitivity across of NSCLC. of cell cancer This and the one run to biopsy X,XXX customers January, non-small for power subjects molecular controls was demonstrated to of the In largest NSCLC liquid diverse date.
in Meeting Last the approach detection. that potential early novel presented new American demonstrated at feasibility they and month, of X biomarker Cancer the their Research data posters Annual discovery Association for for cancer
of from for first DNA Their proteins, leveraged profiling discovery. poster in deep blood metabolites, transcripts biomarker NSCLC patients cell-free and multiomic
interest level for biomarkers resolution of and types individuals identification, discovery. without holding taxed in biomarker NSCLC, cancer. multiple of drive many showed Proteograph all biomarkers with between overlapping with a Data demonstrating distinguish ability the peptide it to significant The and importance to played demonstrated novel across a broad role we
a referred demonstrated poster of multiomic second adenocarcinoma detection or sensitivity P-D-A-C, achieved specificity pancreatic The also as PDAC. classifier for high that ductal and to
combination biomarker identify PrognomIQ into In novel detection multiomic proof-of-concept high-performance control and this of from analytes unknown of controls. and for PDAC known panel study, study the data discrimination levers relations case PDAC XXX non-cancer to in of with both subjects, to
rapid Results feasibility of potentially The support from clinically this high-performance of draws early test of makes development utilization. and approach PDAC. blood as the analytes panels useful amenable for collected detection these to a
of These drive enable the results utilized the biomarkers, can clinical illustrate can beginning will of we just be Proteograph what is then identification believe This hands the customers. how the in Proteograph in application. which novel from PrognomIQ of the
highlighting with Exploris X data technology, and In Proteome Conference, AV Thermo Seer on optimized the Orbitrap using late was method Proteograph the customer FAIMS an including for COVID-XX response at Human March, the there presentation X US and podium Pro. posters Fisher for Organization vaccine
look oral disease samples at X,XXX product in the is customers. using which the the first Alzheimer's plasma cohort our hands presentation access early of approximately next covers The several of
workshop well-attended hosted industry flexibility highlighting a types Proteograph X sample studies. ability with features performance, to We drive to and also presentations address multiple large-scale
are In Society the the at looking forward or annual Mass American XX Seer with exciting abstracts in we and conference, more XX to program. data Spectrometry June, customer ASMS for upcoming
biologic quantitation manufacturing Customer in proteins sensitivity Nonalcoholic others. posters include applications mouse and with for cell pharmacoproteomics using in models, and Steatohepatitis or improved NASH, aging host for an in targeted presentations precision among translational
and we're Thermo SCIEX the with continuing mass these our standardization and to Proteograph spec drive on leading commercial Bruker performance with posters partnership multiple demonstrating platforms. costs, partners, And across and the exceptional Fisher,
are study of myeloma performance in using These show the optimized and HT studies the than deeper us particularly enabled Broad customer Steve the at from ASMS possible. Proteograph dia-PASEF. have timsTOF demonstrating at the mass protocol results with they Proteograph Dr.Carr is note by Bruker into spec patients One how the Carr's get are Institute. Dr. can lab proteome oral from an of larger presentation, skilled plasma as that multiple previously exciting will the
and that achieved this of X,XXX has a remained for published unbiased the in Dr.Carr paper In deep paper plasma XXXX, proteomics proteins plasma, a benchmark depth until now. and seminal
Suite. XX of throughput yet by X,XXX another XXXX the and Proteograph This the Product accomplished proteomic the is complexity samples. study, has Dr.Carr's the increase depth was given example and study workflow of proteins enabled the identified to Importantly, that current samples. step-function is in been being XXX the applied over of on only
is new its with combined multiomic details that follow to their an publications the on of look way notable understand forward is review manuscript of space to InspirationX, into response and beginning It a includes We molecular space make human following significance. study. the of additional see to changes to further project example This the cellular acceleration Proteograph the crew this sharing providing such civilian the opportunities more to in travel. One viewing publication the use data body's to exciting customer-driven of flight. SpaceX of peer occur of to customer data understand
expect market several next emerging in progressive data generation proof is confident coming will feel the and very velocity opportunities as in see novel Proteograph the studies. the third-party We we by the multiple have We [end] by biological the generated customers drive will coming visibility our Proteograph accelerate of increase more adoption to a additional manuscripts months unique and quarters. of insights thrilled and multiomic of about the of being of in to value customers validation more submitted that the
Suite. the Turning Product to second our the attention the power demonstrating of objective, Proteograph
our of own BMPX the abstract highlighted that in was PLOS we and capabilities publication our the at peptide extend of discovered peer or that This variants protein announced level. insights the innovate, ONE. X morphogenetic technology drive progression and Proteograph isoform on to In continue published March, level identifying We cancer paper and bone publication. in our links lung review protein between the importance protein
we unique continue of to advance multiple from expecting ability in months, to technology the released our push workflows science, data are upcoming papers proteomic These of boundaries from their and have our the we proteomics. disruptiveness field its Seer bio-interactions, expect will In what nano customers. and to to large-scale showcasing addition and papers
analysis We and proteomic data. know that that to access interpretation solutions remain cutting-edge delivering key. processing, streamlined drive enabling to We is more data committed
customers to continue deep for will and and Analysis unbiased our the of our will workflow will Proteograph that component scale. large-scale important at road we be XXXX, software We this Throughout to with to map believe serve our Suite. studies an expand more onboard lay enable proteomic capabilities
we spec the mass incorporate base research. be scale, well our into users in exactly installed broad beyond studies believe discussion. very proteomic From the seeing out deep beginning, proteomic engage there play to interest That would is existing plasma at in unbiased we're what of
data the base spec appetite Consistent with sets. multiomic with genomic well our data adding genomic as increased original installed vision, the mass spanning is as the for market large, market opportunity to
capitalize It on serve this with great in already is next feedback is sites, and performance. its meant product need on access getting Our audience. multiple we're a broader to to early
in unbiased same. Our next first does product the a step-function change this product and proteomics delivered
months. forward we We more are to market, about the what really enable will upcoming sharing in the in you look excited and with it
Turning applications new and markets. to our third catalyzing objective,
commercial, markets. a of with technology sample agnostic inherently Our growing It Suite diverse being compatible extensible. PCs pharma, is our is is customer applied types. is translational, Proteograph Product even and of applications in in across research, range CROs and base a used academic The range
One vaccines. reproducible such to a quantitive HCP. application produce high encoded or organism is production dynamic in host-cell of from for of the challenges protein as biopharmaceuticals, is of produced Proteograph HCPs the are protein the Proteograph therapeutic assay, screening by one example those HCP used host high the new biomanufacturing throughput, ideal of Removal this detect that an HCP and customer our proteins or of The base use to emerged fits has recombinant of range. sensitive used with it's bill. biggest the
study A a traditional presented at be purification major In we to the on methods, and of partnership upcoming the Proteograph the than work steps. that in Suite detects XX% measurements across Xx pharmaceutical demonstrated ASMS partner. identifying overall with will Product a HCPs company, this improving more Xx poster biopharma HCPs
capital studies including within a and they even or are submission onboard preliminary own XXX to XX our small results studies for size. process of for proof samples Proteograph insight, equipment from this studies can in in grant the enabler often as on build at These the of biomarkers abstracts value for funding small customers to their key be and find uncovered technology punitive to posters continue academic organization, case principle the Customers as customers.
impairment, dog, Proteograph looking program, tissue have We aging, the transplant. study principal of principle plant shipment use we this baboon multiple in company studies a cancers of With COVID in nonhuman conducted and to proof in exposure, study organization. had demonstrated diet, Proteograph the of for a quarter, following a example, for and the chicken, proof cognitive health our at across small cat, first
as We to efforts accelerate such to continue [indiscernible] development KOL market will work broad enable studies, market adoption. collaborations these drive and and
Biophysics expanding Dr. Kuhn of Kettering board Cancer at the School. Eyk. Law Cornell Mason Professor Jenny and with chemistry we're Rockefeller Dr. WorldQuant as Professor affiliate is Yale and University initiative biomolecular management. at and a Through Mason Harvard Dr. Chemistry scientific a these Weill Wisconsin and leaders a qualitative prediction addition key efforts, physiology building Sloan the Dr. recent Medical advisory of for of Josh in Dr. of relationships the an as our with Chris opinion Memorial Medicine Genomics, well of is Director Center, Kuhn, School and Van of University,
of Clinical Precision As mentioned current Van Research President earlier, well the Institute, Professor Biosystems Cedar-Sinai as Lab HUPO. the Dr. of the Biomarker Cardiology as is at the Eyk of Founder Advanced Director the and of
the to are with future the hands to of possible boundaries power I'm in in multiomics, what's their relationships together. our They're the reinforcing Proteograph these of in These fields. the luminaries excited engagement to us partnering continue push new imagine a of and
turn will Scott update Scott to over be our want our developing team. from thank to call share to July. in and and I transitioning an David, contribution, Officer, the Thomas, I leadership I Before here for leading organization. on his commercial Chief Commercial want
will Presidents senior lead APAC, regional commercial Vice Americas two the respectively. Our and EMEA, in
will to the turn promise our to we're excellent continue call team now David. place, deliver an confident I technology. the With of that, transformational we will over and have We in on
